Rayego-MateosSMorgado-PascualJLValdivielsoJMSanzABBosch-PanaderoERodrigues-DezRRet al
Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, Spana C
In diabetes management, peptide-based drugs are frequently used in combination with small molecule medications such as metformin
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite